M9140 + bevacizumab + capecitabine

M9140 + bevacizumab + capecitabine is a **combination regimen** comprising three components: - **M9140**, a code-name-designated investigational therapy (likely a novel or experimental anti-cancer agent; specific details about its modality and mechanism are not available in public databases as of the search date), - **Bevacizumab**, a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis, and - **Capecitabine**, an oral small molecule prodrug of 5-fluorouracil (5-FU) that interferes with DNA synthesis in dividing cells. This combination is being explored for anticancer effects, leveraging the anti-angiogenic effects of bevacizumab with the cytotoxicity of capecitabine and the investigational action of M9140. Indications would likely be in advanced, metastatic, or refractory cancers responsive to these mechanisms, though no standard indication is established yet due to the investigational status of M9140.